Virtual screening of 57 galectin-3 inhibitors was accomplished and 37 have known affinity to galectin-3. The purpose was to virtually test the idea of a double inhibitor that prevents viral entry and reduces post-infection pulmonary fibrosis. Many existing galectin-3 inhibitors possess this dual binding capability, disrupting Spike - ACE2 interactions. Five targets emerged as effective dual inhibitors and warranted further testing.
